Covers a programmable nanohybrid platform that profiles extracellular vesicle metabolites in native biofluids to map tumour metabolic changes and prognosis.
Key Takeaways
- View all journals Current technologies for measuring cancer metabolism have limited clinical utility
- Termed atomically configured catalytic hybrids for profiling extracellular vesicle metabolites (ACTIVE)
- Additional data that support the findings of this study are available from the corresponding author upon request